Provided is an influenza vaccine composition based on a novel ribonucleic acid having a dual function of serving as an immunity-boosting agent and capturing antigens.

A CMV-based vaccine that promotes immune-mediated destruction of cancer through a onetime or repeated intratumoral administration of a recombinant CMV to generate a robust, long-lasting anti-tumor immune response.

The present disclosure relates to vaccine compositions comprising a) antigens from at least three different strains of influenza vims, preferably at least four different strains of influenza vims, and b) an oil-in-water emulsion adjuvant, wherein the amount of the oil-in-water emulsion adjuvant is greater than an amount of an oil-in-water emulsion adjuvant in a standard-dose adjuvanted multivalent influenza vaccine. Additionally, the total amount of the antigens in the vaccine compositions may be greater than a total amount of antigens in a standard-dose adjuvanted multivalent influenza vaccine. In preferred aspects, the present disclosure further describes uses of these vaccine compositions for safe and effective induction of immune responses in adults at least 65 years of age.

The invention reported here relates to a method for preparation of inactivated SARS-CoV-2 vaccine by exposing the virus (SARS-CoV-2) to a predetermined concentration of an inactivating psoralen compound, and a preselected intensity of ultraviolet A (UVA) radiation for a preselected time period long enough to render the virus inactive but short enough to prevent degradation of its antigenic characteristics.

Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from an attenuated or wild-type dengue serotype 2 virus (DENV-2), and a portion of a prM signal sequence, a prM protein and at least a portion of an envelope (E) protein from a Zika virus (ZIKV) are described. Also described are immunogenic compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV.

The invention relates to vaccines for the prevention or treatment of infectious diseases, and to methods of preparing or delivering such vaccines. In particular, a vaccine for use in the prevention or treatment of disease is used in a dose of, via a parenteral route without adjuvant less than 0.03 .Math.g antigen and with adjuvant less than 0.003 .Math.g antigen, and via a mucosal route without adjuvant less than 1 .Math.g antigen and/or the equivalent of 1.6 × 10.sup.7 PFU and with adjuvant less than 0.04 .Math.g antigen and/or the equivalent of 1.6 × 10.sup.7 PFU

The present invention relates to a novel genotype of severe fever with thrombocytopenia syndrome viruses and use thereof as an immunogenic composition. The severe fever with thrombocytopenia syndrome viruses of the present invention are genetically different from conventional severe fever with thrombocytopenia syndrome viruses and are novel viruses taxonomically belonging to three sub-groups of genotype B. In view of the vaccine property that specific genotype viruses alone show only limited protective potential, the novel viruses of the present invention may be advantageously used as a vaccine having excellent cross-immunogenicity for SFTSV.

An engineered vaccinia virus, a pharmaceutical composition containing the same, and methods for use in treating a subject in need using the same are provided. The engineered vaccinia virus includes a mutated viral sequence and a heterologous sequence. The mutated viral sequence is used for selective replication in tumor cells and/or activation of immune cells. The heterologous sequence encodes an immune co-stimulatory pathway activating molecule, immunomodulator gene, a truncated viral envelope gene, and/or a tumor suppressor. The heterologous sequence is stably incorporated into the genome of the engineered vaccinia virus. The pharmaceutical composition includes an effective amount of the engineered vaccinia virus and a pharmaceutical acceptable vehicle. The methods for use in treating the subject in need include administering the engineered vaccinia virus to the subject.

Modified influenza virus neuraminidases are described herein that have stabilized NA tetramers which may improve vaccine production efficiency, thus improving the yield of vaccine viruses.

Provided is a method for producing an influenza HA split vaccine which produces an antibody that binds to an HA stem region of influenza, the HA stem region being less likely to cause antigenic variation, An influenza HA split vaccine is subjected to an acidic treatment. Through the acidic treatment, an influenza HA split vaccine which produces an antibody that binds to an LAH of the HA stem region is obtained. This influenza HA split vaccine has an excellent ability against infection of other influenza viruses of different antigenicity.